We recently compiled a list of the 10 Best Small-Cap Stocks Ready To Explode. In this article, we are going to take a look at where Neumora Therapeutics, Inc. (NASDAQ:NMRA) stands against the other small-cap stocks.
Prospects For Extended Outperformance Of Small-Cap Stocks
On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief Investment Officer and Managing Director of Royce Investment, discussed the outperformance of small-cap stocks. While discussing the reasons that led to the Russell 2000 Index doing well in Q3 ’24, Gannon noted that the strong performance of the Russell 2000 Index, which was up 9.3%, in the third quarter of 2024 can be attributed to a “quintessential reversion to the mean,” as small-caps had lagged behind larger companies for an extended period. He thinks that the rebound was not surprising given the historical trends, as the small-cap index outperformed the large-cap Russell 1000, up 6.1%, and the mega-cap Russell Top 50, up 4.2% during this time.
Read Also: 7 Best Nano Cap Stocks To Invest In and 10 High Growth Non-Tech Stocks That Are Profitable in 2024.
On the other hand, Royce mentioned that he was surprised by the concentration of the small-cap gains. He noted that all the gains for the quarter were compressed at the start, as by early July 16, the index had already achieved a 10.6% increase from the end of June, marking its high for the quarter. Royce further mentioned that this rapid ascent was followed by a notable decline, with the index dropping 10.1% from July 16 to August 7 before recovering most of its losses by the end of September. Despite this volatility, he expressed satisfaction with the small-cap performance overall for the quarter, especially since it marked a reversal after small-caps last outperformed large-caps in Q4 2023.
Building further upon the volatility of small-cap stocks, Royce expressed that while volatility in small-cap stocks can be concerning, it is a normal part of investing in this asset class. He emphasized that they welcome volatility as it allows them to take advantage of price fluctuations for long-term gains. Historically, significant intra-year declines are common for small-caps, with the Russell 2000 experiencing double-digit pullbacks in 22 out of the last 25 years.
While answering how the sector can sustain its market leadership performance, Gannon highlighted that market breadth among large caps often leads to better performance for small caps. He pointed out that when the equal-weighted Russell 1000 outperformed its capitalization-weighted counterpart, small-caps typically led in performance. This trend suggests that an expansion of returns across different sectors is a positive indicator for small-cap stocks.
Moreover, both Royce and Gannon stressed that earnings growth is crucial for the long-term success of small-cap stocks. Gannon stated that while short-term market psychology can influence stock prices, consistent earnings are fundamental for sustaining long-term performance. He noted that despite a significant portion of small-cap companies lacking earnings, around 44.6%, those with earnings are expected to grow faster than their large-cap counterparts in 2025.
Our Methodology
To curate the list of 10 best small-cap stocks ready to explode we used the Finviz stock screener and CNN. Using the screener we shortlisted small-cap stocks (market-cap between $500 million to $2 billion) for which analysts are expecting more than 50% upside from the current stock price. Once we had shortlisted the stocks we cross-checked the analysts’ upside potential from CNN. Lastly, we ranked the stocks based on the ascending order of the analyst upside potential. Please note that the data was recorded on November 15, 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A clinical researcher in a lab examining a new biopharmaceutical product.
Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Analyst Upside Potential: 112.18%
Neumora Therapeutics, Inc. (NASDAQ:NMRA) ranks as the 7th best small-cap stock ready to explode. Analysts’ 12-month median price target is pointing towards a 112.18% upside from current levels. It is a biopharmaceutical company focused on developing new treatments for brain diseases. It operates in the clinical stage, meaning it is working on medications that are being tested in humans to see if they are safe and effective.
The company has a pipeline of seven programs aimed at treating various neuropsychiatric disorders (like depression and schizophrenia) and neurodegenerative diseases (such as Alzheimer’s). These programs explore new ways to interact with the brain’s chemistry to improve treatment outcomes for conditions that currently have limited options.
One of their main drug candidates is navacaprant (NMRA-140), which is designed to treat major depressive disorder (MDD). This medication works by blocking specific receptors in the brain that are linked to mood regulation. During the third quarter results for fiscal 2024, Neumora Therapeutics, Inc. (NASDAQ:NMRA) announced that it is currently enrolling in the registrational Phase 3 KOASTAL program, which is designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of MDD. Management expects topline data from the program by the end of 2024 and topline results from KOASTAL 2 and KOSTAL 3 programs during the first half of 2025.
NMRA-140 is a significant treatment for the company as it treats MDD, as per management statistics MDD is a leading cause of disability around the world, and around 280 million people suffer from the disease worldwide. NMRA-140 has the potential to reshape the treatment of depression. Neumora Therapeutics, Inc. (NASDAQ:NMRA) believes that its pipeline has the potential to reach up to 40 million patients in 2026 bringing significant revenue as it enters the commercial stage.
As of November 12, the company had $341.3 million in cash, cash equivalents, and marketable securities, which the management believes is sufficient to support operations into mid-2026.
Overall NMRA ranks 5th on our list of the best small-cap stocks to buy. While we acknowledge the potential of NMRA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for a promising AI stock that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
